Coté Orphan Boot Camp will include key players of the regulatory affairs industry. Attendees will learn first-hand how orphan drugs are managed with special deference by regulatory agencies such as the FDA and EMA. This one-day seminar is a unique and free opportunity to hear from the former head of the FDA orphanage just how things are viewed from the inside.
The Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location.
Now in its 19th year, the SBD is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association’s Annual General Assembly. As always, the event targets entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders.
Coté Orpan Boot Camp will include key players of the regulatory affairs industry. Attendees will learn first-hand how orphan drugs are managed with special deference by regulatory agencies such as the FDA and EMA. This one-day seminar is a unique and free opportunity to hear from the former head of the FDA orphanage just how things are viewed from the inside. Meet us there!
Each year the event draws over 1,000 attendees from New York and across the Northeast, as well as a global audience including attendees from Europe and Asia.
The theme of the 2017 Annual Conference is "New York Life Science at a Tipping Point."
Over the past several years, the New York life science ecosystem has seen huge growth in industry development, venture investment, commercial expansion, and patient relations. But it has taken a long time to get this point, and the industry has had some significant set backs. The 2017 Annual Conference will therefore be a frank and open discussion of the issues—the good, the bad, and the ugly—of New York’s life science scene as it exists today and what may be the strengths, weaknesses, opportunities, and threats to it. What have we done right? What have we done wrong? What lessons can be learned and applied?
he BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
At the World Orphan Drug Congress USA in April 2017, we are bringing together more than 150 elite speakers to educate and inspire our 1,000 attendees from big pharma, biotech, payers, patient groups, academics and government bodies. In 2017, World Orphan Drug Congress USA is bringing together the worlds of Scientific Innovation and Commercialization, with 2 tracks in the main conference.
By exploring trends in Digital Health, Biosimilars, Gene Therapy, and more, we will uncover the next scientific breakthrough. Examinations of Mergers, Commercialization, Marketing and the Regional Markets will provide insight into this billion-dollar business. That's not all with Rare Disease Advocacy World and Pitch and Partner 2017, there are 4 tracks of content for you and your team to enjoy.
- See more at: http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm#sthash.3XNgFgaf.dpuf
Coté Orpan Road Show will include key players of the regulatory affairs industry. Attendees will learn first-hand how orphan drugs are managed with special deference by regulatory agencies such as the FDA and EMA. This half-day seminar is a unique and free opportunity to hear from the former head of the FDA orphanage just how things are viewed from the inside.
The 12th anniversary of leading Korean bio-industry’s future.
BIO KOREA isan effective business place has galvanised into bio-industry. Also, It is the place of the international information exchange and technology Transfer.
The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more. The RESI Partnering Forum allows fundraising executives to identify and book up to 16 meetings with life science investors who fit their company’s technology sector and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.
The MassBio Annual Meeting focuses on the timeliest and critical challenges facing the Massachusetts life sciences industry. The meeting program is designed by a steering committee of industry leaders and the agenda encompasses keynote presentations, panel discussions, interactive working sessions and extensive networking opportunities.
The premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe's most innovative biopharma clusters
The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.
The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more.
Biocom's 7th Annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies.
The conference will include panel discussions on relevant topics with senior industry leaders, start-up company presentations, one-on-one meetings, and numerous networking opportunities.
Coté Orpan Boot Camp will include key players of the regulatory affairs industry. Attendees will learn first-hand how orphan drugs are managed with special deference by regulatory agencies such as the FDA and EMA. This one-day seminar is a unique and free opportunity to hear from the former head of the FDA orphanage just how things are viewed from the inside. Ask here for more details.
Cote Orphan LLC is excited to announce its newest location in Boston/Cambridge, MA. Please come and enjoy an evening of networking with Dr. Tim Cote, the Boston staff, and biotech industry leading partners to learn about consultant services available.
The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
This event continues to be one of the life science industry’s largest conferences of the year. It brings thousands of investors and executives from around the world to San Francisco where companies present their latest innovations hoping to find their next partner or investor.
The 2nd Annual Oncolytic Virotherapy Summit is dedicated to foster the next wave of genetically modified viruses that target, replicate and kill cancer cells in a clinical setting, spurred on by advanced genetic engineering techniques.
By better understanding oncolytic platforms, preclinical virotherapy models, clinical strategy and scalable manufacture of viruses, Oncolytic Virotherapy Summit is the only industry-focused gatheringallowing you to capitalize on this inflection point and enhance the translation of innovative basic research into the next generation of clinically-relevant virotherapeutics.
The (GROD 2016) Global Summit on Rare Diseases & Orphan Drugs is an International Rare Diseases Conference, encompassing genetically caused rare diseases and fundamental research and development in respective field. It is a Global platform reaching across all the rare diseases around the globe, covers research and developments of new treatments. The conference attains significance when we look at the worldwide deaths due to Rare Diseases, about 30 percent of children with rare diseases will die before reaching their fifth birthday. Plus, you'll have the opportunity to connect with more than 500 of your peers and celebrate your profession. You'll leave better educated and more invigorated than you thought possible. We wish to see you in 'Dubai' a capital city of united arab emirates, and a promising place to discover novel things in the field of science and technology.
We invite you to attend the 5th Oncology Partnering & Deal-Making Conference, which will take place November 8-9, 2016 in San Francisco, CA. This event is a partnership and business development conference that provides an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the industry.
Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, innovative partnering for value creation, and landscape of Immuno-oncology. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum!
The 22nd annual BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry.
This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking. Meet us there!
The Priority Review Voucher Program was created as an incentive for pharmaceutical companies to develop drugs for neglected diseases. In order to receive a priority review voucher (PRV), a product application must meet the criteria of the Neglected Tropical Disease or Rare Pediatric Disease PRV Programs. Neglected tropical diseases are infectious diseases that affect more than a billion people in 149 countries, most of which are in the developing world. A rare pediatric disease is a disease that affects fewer than 200,000 individuals in the United States, of which greater than 50% of the affected population is 18 or under.
The Nordic region is proud to host some of the world’s most innovative biotech, medtech and pharma companies. It also has the 12th strongest economy, making it the perfect place to invest. Set in the idyllic city of Stockholm, the conference offers conference sessions, panel discussions, company presentations, exhibition, face-to-face meetings and unique receptions, providing so many opportunities to network with peers, potential partners and investors. Meet us there!
Dr. Tim Cote will be hosting a webinar outlining:
- The differences in obtaining approval for orphan vs. non-orphan drugs
- Detail prevalent criteria for orphan drugs
- The clinical superiority in orphan drug designation
- What is a “typical orphan drug”
For more information and a VIP discount code, contact us here
Orphan Drugs & Rare Diseases Global Congress 2016 Americas will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, nonprofit organizations, orphan drugs developers as well as regional and local manufacturers.
The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. We offer unparralled partnering opportunities, an outstanding education program, an expansive exhibition floor, and exclusive networking events where you'll access over 2,500 CEO's from leading biotech companies.
World Orphan Drug Congress USA 2016 will be the benchmark for doing business when it comes to technology and innovation. And you can be there with us. Download the preview agenda for more information on how your company can partner with event to meet new clients and increase your sales.
BIO-Europe Spring® is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking.